{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:07:10Z","timestamp":1789124830938,"version":"build-2803163510"},"reference-count":334,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.addr.2026.115938","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:14:42Z","timestamp":1785338082000},"page":"115938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Intranasal drug delivery to the brain for neurodegenerative diseases: Current efforts and challenges in delivery platforms and modeling"],"prefix":"10.1016","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6093-1552","authenticated-orcid":false,"given":"Katherine Y.","family":"Bang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-4245","authenticated-orcid":false,"given":"Ross","family":"Walenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6442-9787","authenticated-orcid":false,"given":"Steven","family":"Chopski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6887-3156","authenticated-orcid":false,"given":"Markham C.","family":"Luke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1123-3152","authenticated-orcid":false,"given":"Ksenia","family":"Blinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0257-9082","authenticated-orcid":false,"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-0108","authenticated-orcid":false,"given":"Su","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115938_bb0005","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/alz.12362","article-title":"Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060)","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.addr.2026.115938_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102357","article-title":"Neurodegenerative disorders: mechanisms of degeneration and therapeutic approaches with their clinical relevance","volume":"99","author":"Gadhave","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.addr.2026.115938_bb0015","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","volume":"19","author":"2023 Alzheimer's disease facts and figures","year":"2023","journal-title":"Alzheimers Dement."},{"issue":"2019","key":"10.1016\/j.addr.2026.115938_bb0020","first-page":"459","article-title":"Neurology collaborators, global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"GBD","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.addr.2026.115938_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.addr.2026.115938_bb0030","series-title":"The Economic and Societal Burden of Alzheimer Disease: Managed Care Considerations","volume":"28","author":"Skaria","year":"2022"},{"key":"10.1016\/j.addr.2026.115938_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-020-0117-1","article-title":"Current and projected future economic burden of Parkinson's disease in the U.S","volume":"6","author":"Yang","year":"2020","journal-title":"Npj Parkinsons Dis."},{"key":"10.1016\/j.addr.2026.115938_bb0040","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115938_bb0045","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.3390\/ijms10062510","article-title":"Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders","volume":"10","author":"Choonara","year":"2009","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb0050","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of neurodegenerative diseases","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.addr.2026.115938_bb0055","doi-asserted-by":"crossref","first-page":"12486","DOI":"10.3390\/ijms241512486","article-title":"Exploring molecular targets for mitochondrial therapies in neurodegenerative diseases","volume":"24","author":"Plascencia-Villa","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb0060","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41551-020-0593-y","article-title":"Defining and predicting transdiagnostic categories of neurodegenerative disease","volume":"4","author":"Cornblath","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.addr.2026.115938_bb0065","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.3390\/ijms24032117","article-title":"Neurons, nose, and neurodegenerative diseases: olfactory function and cognitive impairment","volume":"24","author":"Fatuzzo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb0070","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1038\/s41467-021-26045-w","article-title":"Antigen presentation by lung epithelial cells directs CD4+ TRM cell function and regulates barrier immunity","volume":"12","author":"Shenoy","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115938_bb0075","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1465-9921-13-80","article-title":"The dendritic cell niche in chronic obstructive pulmonary disease","volume":"13","author":"Haczku","year":"2012","journal-title":"Respir. Res."},{"key":"10.1016\/j.addr.2026.115938_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104700","article-title":"Autonomic dysfunction in Parkinson's disease: implications for pathophysiology, diagnosis, and treatment","volume":"134","author":"Chen","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.addr.2026.115938_bb0085","first-page":"fcac109","article-title":"Structural progression of Alzheimer's disease over decades: the MRI staging scheme, brain","volume":"4","author":"Planche","year":"2022","journal-title":"Communications"},{"key":"10.1016\/j.addr.2026.115938_bb0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","article-title":"Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation","volume":"22","author":"Mead","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115938_bb0095","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5114\/fn.2020.96707","article-title":"What causes neurodegenerative disease?","volume":"58","author":"Armstrong","year":"2020","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.addr.2026.115938_bb0100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.biopsych.2015.08.013","article-title":"Alpha-Synuclein produces early behavioral alterations via striatal cholinergic synaptic dysfunction by interacting with GluN2D N-methyl-D-aspartate receptor subunit","volume":"79","author":"Tozzi","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.addr.2026.115938_bb0105","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic interactions between a\u03b2, tau, and \u03b1-Synuclein: acceleration of neuropathology and cognitive decline","volume":"30","author":"Clinton","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.addr.2026.115938_bb0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13195-024-01463-2","article-title":"Cerebrospinal fluid \u03b1-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults","volume":"16","author":"Liu","year":"2024","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.addr.2026.115938_bb0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12877-016-0342-y","article-title":"Environmental risk factors for dementia: a systematic review","volume":"16","author":"Killin","year":"2016","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.addr.2026.115938_bb0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10654-014-9887-2","article-title":"Reduced risk of Parkinson's disease associated with lower body mass index and heavy leisure-time physical activity","volume":"29","author":"S\u00e4\u00e4ksj\u00e4rvi","year":"2014","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.addr.2026.115938_bb0125","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1038\/cddis.2012.50","article-title":"Increased \u03b1-synuclein phosphorylation and nitration in the aging primate substantia nigra","volume":"3","author":"McCormack","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2026.115938_bb0130","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.arcmed.2012.11.003","article-title":"Epidemiology of dementias and Alzheimer's disease","volume":"43","author":"Sosa-Ortiz","year":"2012","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.addr.2026.115938_bb0135","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1212\/WNL.0b013e3182553be6","article-title":"Is dementia incidence declining?: Trends in dementia incidence since 1990 in the rotterdam study","volume":"78","author":"Schrijvers","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2026.115938_bb0140","series-title":"Incidence and Prevalence of Dementia in the Cardiovascular Health Study - Fitzpatrick - 2004 - Journal of the American Geriatrics Society","year":"2026"},{"key":"10.1016\/j.addr.2026.115938_bb0145","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/ijms23031851","article-title":"A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of Nanotherapeutics","volume":"23","author":"Lamptey","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb0150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson's disease","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115938_bb0155","unstructured":"Treatment of Alzheimer disease - UpToDate, (2026). n.d. https:\/\/www.uptodate.com\/contents\/treatment-of-alzheimer-disease (accessed November 8, 2024)."},{"key":"10.1016\/j.addr.2026.115938_bb0160","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","article-title":"Guideline subcommittee of the AAN, dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN guideline subcommittee","volume":"97","author":"Pringsheim","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2026.115938_bb0165","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00002826-199508000-00006","article-title":"Pramipexole in patients with early Parkinson's disease","volume":"18","author":"Hubble","year":"1995","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.addr.2026.115938_bb0170","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","article-title":"Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease","volume":"68","author":"Watts","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2026.115938_bb0175","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1212\/WNL.49.2.393","article-title":"Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group","volume":"49","author":"Adler","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2026.115938_bb0180","series-title":"Medical management of motor fluctuations and dyskinesia in Parkinson disease - UpToDate","year":"2026"},{"issue":"Suppl. 4","key":"10.1016\/j.addr.2026.115938_bb0185","first-page":"S13","article-title":"Management of Parkinson\u2019s disease","volume":"17","author":"Amantadine and other antiglutamate agents","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.addr.2026.115938_bb0190","series-title":"Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches \u2013 PubMed","year":"2026"},{"key":"10.1016\/j.addr.2026.115938_bb0195","series-title":"Initial pharmacologic treatment of Parkinson disease - UpToDate","year":"2026"},{"key":"10.1016\/j.addr.2026.115938_bb0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40035-024-00397-x","article-title":"The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing","volume":"13","author":"Liu","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.addr.2026.115938_bb0205","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"L\u00f3pez-Ot\u00edn","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115938_bb0210","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3233\/JAD-240620","article-title":"Alzheimer's disease: an attempt of Total recall","volume":"101","author":"Bolshakov","year":"2024","journal-title":"J. Alzheimer's Dis"},{"key":"10.1016\/j.addr.2026.115938_bb0215","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/85059","article-title":"Mice deficient in BACE1, the Alzheimer's \u03b2-secretase, have normal phenotype and abolished \u03b2-amyloid generation","volume":"4","author":"Luo","year":"2001","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.addr.2026.115938_bb0220","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer's disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.addr.2026.115938_bb0225","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature11729","article-title":"NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP\/PS1 mice","volume":"493","author":"Heneka","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115938_bb0230","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41586-022-04640-1","article-title":"Somatic genomic changes in single Alzheimer's disease neurons","volume":"604","author":"Miller","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115938_bb0235","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s42003-022-03312-0","article-title":"Failure of DNA double-strand break repair by tau mediates Alzheimer\u2019s disease pathology in vitro","volume":"5","author":"Asada-Utsugi","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.addr.2026.115938_bb0240","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nn.3356","article-title":"Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-\u03b2","volume":"16","author":"Suberbielle","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.addr.2026.115938_bb0245","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1021\/acschemneuro.4c00339","article-title":"Alzheimer's disease: exploring the landscape of cognitive decline","volume":"15","author":"Tenchov","year":"2024","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.addr.2026.115938_bb0250","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing","volume":"51","author":"Kunkle","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2026.115938_bb0255","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1038\/s41598-021-82901-1","article-title":"Astrocytic expression of the Alzheimer's disease risk allele, ApoE\u03b54, potentiates neuronal tau pathology in multiple preclinical models","volume":"11","author":"Jablonski","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2026.115938_bb0260","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s43587-023-00368-3","article-title":"Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits","volume":"3","author":"Koutsodendris","year":"2023","journal-title":"Nat. Aging"},{"key":"10.1016\/j.addr.2026.115938_bb0265","doi-asserted-by":"crossref","first-page":"74","DOI":"10.32481\/djph.2021.09.009","article-title":"Diagnosis and treatment of Alzheimer's disease: an update","volume":"7","author":"Bomasang-Layno","year":"2021","journal-title":"Delaware J. Public Health"},{"key":"10.1016\/j.addr.2026.115938_bb0270","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer's disease: causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115938_bb0275","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","article-title":"Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline","volume":"148","author":"Raina","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2026.115938_bb0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115938_bb0285","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"TRAILBLAZER-ALZ 2 investigators, Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 Randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2026.115938_bb0290","series-title":"Mayo Clinic","author":"How Alzheimer's medicines help manage symptoms","year":"2026"},{"key":"10.1016\/j.addr.2026.115938_bb0295","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2026.115938_bb0300","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.addr.2026.115938_bb0305","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/193229680800200619","article-title":"Alzheimer's disease is type 3 diabetes\u2014evidence reviewed","volume":"2","author":"de la Monte","year":"2008","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2026.115938_bb0310","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","article-title":"Intranasal insulin improves cognition and modulates \u03b2-amyloid in early AD","volume":"70","author":"Reger","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.addr.2026.115938_bb0315","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","article-title":"Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial","volume":"77","author":"Craft","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.addr.2026.115938_bb0320","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3233\/JAD-141791","article-title":"Long-acting intranasal insulin Detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia","volume":"44","author":"Claxton","year":"2015","journal-title":"J. Alzheimer's Dis"},{"key":"10.1016\/j.addr.2026.115938_bb0325","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.addr.2026.115938_bb0330","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1007\/s13346-024-01558-1","article-title":"Insulin delivery to the brain via the nasal route: unraveling the potential for Alzheimer's disease therapy","volume":"14","author":"Wong","year":"2024","journal-title":"Drug Deliv. and Transl. Res."},{"key":"10.1016\/j.addr.2026.115938_bb0335","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115938_bb0340","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"\u0391-Synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115938_bb0345","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous \u03b1-Synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.addr.2026.115938_bb0350","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/jamaneurol.2014.2704","article-title":"Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease","volume":"72","author":"Kalia","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.addr.2026.115938_bb0355","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.addr.2026.115938_bb0360","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41531-026-01292-0","article-title":"SNCA triplication disrupts proteostasis and extracellular architecture prior to neurodegeneration in human midbrain organoids","volume":"12","author":"Statoulla","year":"2026","journal-title":"Npj Parkinsons Dis."},{"key":"10.1016\/j.addr.2026.115938_bb0365","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41531-024-00660-y","article-title":"G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage","volume":"10","author":"Pena","year":"2024","journal-title":"Npj Parkinsons Dis."},{"key":"10.1016\/j.addr.2026.115938_bb0370","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1093\/hmg\/ddad102","article-title":"Mitochondrial dysfunction and mitophagy defects in LRRK2-R1441C Parkinson's disease models","volume":"32","author":"Williamson","year":"2023","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2026.115938_bb0375","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1474-4422(14)70287-X","article-title":"Prediagnostic presentations of Parkinson's disease in primary care: a case-control study","volume":"14","author":"Schrag","year":"2015","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.addr.2026.115938_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2017.00037","article-title":"Exploring Braak's hypothesis of Parkinson's disease","volume":"8","author":"Rietdijk","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.addr.2026.115938_bb0385","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.addr.2026.115938_bb0390","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41531-022-00436-2","article-title":"A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson's disease","volume":"8","author":"Borghammer","year":"2022","journal-title":"Npj Parkinsons Dis."},{"key":"10.1016\/j.addr.2026.115938_bb0395","series-title":"Initial pharmacologic treatment of Parkinson disease - UpToDate","year":"2026"},{"key":"10.1016\/j.addr.2026.115938_bb0400","first-page":"1044","article-title":"Parkinson study group, Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.addr.2026.115938_bb0405","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115938_bb0410","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.addr.2026.115938_bb0415","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.addr.2026.115938_bb0420","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/bcpt.14042","article-title":"Biomarkers of Parkinson's disease in perspective of early diagnosis and translation of neurotrophic therapies","volume":"135","author":"Tuominen","year":"2024","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.addr.2026.115938_bb0425","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1007\/s00415-023-11893-x","article-title":"Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease","volume":"270","author":"Angius","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.addr.2026.115938_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1102809","article-title":"Reconsidering the role of blood-brain barrier in Alzheimer's disease: from delivery to target","volume":"15","author":"Sousa","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.addr.2026.115938_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113320","article-title":"Alzheimer's disease and its treatment by different approaches: a review","volume":"216","author":"Srivastava","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115938_bb0440","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","article-title":"APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115938_bb0445","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.3390\/pharmaceutics15112599","article-title":"Non-Invasive Drug Delivery across the Blood\u2013Brain Barrier: A Prospective Analysis","volume":"15","author":"Niazi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb0450","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1148\/radiol.2016152444","article-title":"Focused ultrasound enhances central nervous system delivery of bevacizumab for malignant glioma treatment","volume":"281","author":"Liu","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.addr.2026.115938_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113305","article-title":"Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: at a glance","volume":"153","author":"Rahman","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2026.115938_bb0460","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115938_bb0465","article-title":"Neurodegenerative diseases: multifactorial conformational diseases and their therapeutic interventions","volume":"2013","author":"Sheikh","year":"2013","journal-title":"J Neurodegener Dis"},{"key":"10.1016\/j.addr.2026.115938_bb0470","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jalz.2010.04.006","article-title":"Alzheimer disease, a multifactorial disorder seeking multi-therapies","volume":"6","author":"Iqbal","year":"2010","journal-title":"Alzheimer's & Dementia\u00a0: The J. Alzheimer's Association"},{"key":"10.1016\/j.addr.2026.115938_bb0475","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40005-022-00589-5","article-title":"Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors","volume":"53","author":"Jeong","year":"2023","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.addr.2026.115938_bb0480","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.apsb.2021.02.012","article-title":"Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies","volume":"11","author":"Costa","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2026.115938_bb0485","article-title":"On a highway to the brain: a review on nose-to-brain drug delivery using nanoparticles","volume":"29","author":"Formica","year":"2022","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.addr.2026.115938_bb0490","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neulet.2012.02.037","article-title":"Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway","volume":"513","author":"Renner","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.addr.2026.115938_bb0495","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40035-025-00481-w","article-title":"Nose-to-brain drug delivery: from bench to bedside","volume":"14","author":"Drath","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.addr.2026.115938_bb0500","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.3390\/molecules14093754","article-title":"Nasal delivery of high molecular weight drugs","volume":"14","author":"Ozsoy","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115938_bb0505","article-title":"The nose has it: opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters","volume":"21","author":"Chung","year":"2022","journal-title":"Epilepsy Behavior Reports"},{"key":"10.1016\/j.addr.2026.115938_bb0510","first-page":"328","article-title":"Factors affecting nasal drug delivery and design strategies for intranasal drug delivery","volume":"52","author":"Hu","year":"2023","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.addr.2026.115938_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115196","article-title":"Intranasal drug delivery: the interaction between nanoparticles and the nose-to-brain pathway","volume":"207","author":"Chen","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115938_bb0520","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0036-1597950","article-title":"Nasal anatomy and function","volume":"33","author":"Patel","year":"2017","journal-title":"Facial Plast. Surg."},{"key":"10.1016\/j.addr.2026.115938_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1214450","article-title":"Lipid-based nanoparticles via nose-to-brain delivery: a mini review","volume":"11","author":"Xinchen","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.addr.2026.115938_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107321","article-title":"Nanotechnology prospects in brain therapeutics concerning gene-targeting and nose-to-brain administration","volume":"26","author":"Wu","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.addr.2026.115938_bb0535","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.apsb.2022.07.003","article-title":"Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders","volume":"13","author":"Awad","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2026.115938_bb0540","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1341295","article-title":"Research progress in brain-targeted nasal drug delivery","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.addr.2026.115938_bb0545","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3390\/pharmaceutics15061720","article-title":"The Upper Nasal Space: Option for Systemic Drug Delivery, Mucosal Vaccines and Nose-to-Brain","volume":"15","author":"Shrewsbury","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb0550","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jconrel.2023.12.054","article-title":"Nanotechnology for enhanced nose-to-brain drug delivery in treating neurological diseases","volume":"366","author":"Huang","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115938_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb0560","first-page":"116","article-title":"Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture","volume":"10","author":"G\u00e4nger","year":"2018","journal-title":"Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa, Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb0565","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1767","article-title":"Direct nose to the brain nanomedicine delivery presents a formidable challenge","volume":"14","author":"Yokel","year":"2022","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115938_bb0570","series-title":"Direct Nose-to-Brain Drug Delivery","first-page":"287","article-title":"Chapter 15 - diagnostic and theranostic intranasal nanointerventions for brain diseases","author":"Upadhaya","year":"2021"},{"key":"10.1016\/j.addr.2026.115938_bb0575","doi-asserted-by":"crossref","first-page":"8307","DOI":"10.1021\/acs.chemrev.4c00009","article-title":"Ultrasound-based Micro-\/Nanosystems for biomedical applications","volume":"124","author":"Huang","year":"2024","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2026.115938_bb0580","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/pharmaceutics16040481","article-title":"Nasal delivery to the brain: harnessing nanoparticles for effective drug transport","volume":"16","author":"Gandhi","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb0585","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2147\/IJN.S439181","article-title":"Recent advances in intranasal Administration for Brain-Targeting Delivery: a comprehensive review of lipid-based nanoparticles and stimuli-responsive gel formulations","volume":"19","author":"Koo","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2026.115938_bb0590","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jconrel.2022.03.017","article-title":"Nose-to-brain\/spinal cord delivery kinetics of liposomes with different surface properties","volume":"344","author":"Kurano","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115938_bb0595","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2133\/dmpk.22.206","article-title":"Influence of formulation viscosity on drug absorption following nasal application in rats","volume":"22","author":"Furubayashi","year":"2007","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.addr.2026.115938_bb0600","first-page":"rqac003","article-title":"Formulation, design and strategies for efficient nanotechnology-based nasal delivery systems, Rps","volume":"1","author":"de Barros","year":"2022","journal-title":"Pharm. Pharmacol. Rep."},{"key":"10.1016\/j.addr.2026.115938_bb0605","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s11095-011-0417-6","article-title":"Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast","volume":"28","author":"Kundoor","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115938_bb0610","doi-asserted-by":"crossref","DOI":"10.1002\/mame.202400356","article-title":"In situ gels for nasal delivery: formulation, characterization and applications","volume":"310","author":"Qian","year":"2025","journal-title":"Macromol. Mater. Eng."},{"key":"10.1016\/j.addr.2026.115938_bb0615","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.2147\/IJN.S265659","article-title":"Nose-to-brain delivery by Nanosuspensions-based in situ gel for Breviscapine","volume":"15","author":"Chen","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2026.115938_bb0620","doi-asserted-by":"crossref","first-page":"29779","DOI":"10.1021\/acsnano.4c09449","article-title":"Intranasal carrier-free Nanomodulator addresses both symptomatology and etiology of Alzheimer's disease by restoring neuron plasticity and reprogramming lesion microenvironment","volume":"18","author":"Yang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115938_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113604","article-title":"A nasally administrated reactive oxygen species-responsive carrier-free gene delivery nanosystem for Alzheimer's disease combination therapy","volume":"381","author":"Chen","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115938_bb0630","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1016\/j.apsb.2025.02.035","article-title":"Nose-to-brain delivery of targeted lipid nanoparticles as two-pronged \u03b2-amyloid nanoscavenger for Alzheimer's disease therapy","volume":"15","author":"Xu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2026.115938_bb0635","first-page":"207","article-title":"Recent advances in intranasal liposomes for drug","volume":"15","author":"Duong","year":"2023","journal-title":"Gene, and Vaccine Delivery, Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb0640","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.3390\/molecules25235672","article-title":"Recent Progress in bioconjugation strategies for liposome-mediated drug delivery","volume":"25","author":"Almeida","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115938_bb0645","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1208\/s12249-022-02209-9","article-title":"Donepezil HCl liposomes: development, characterization, cytotoxicity, and pharmacokinetic study","volume":"23","author":"Rajput","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2026.115938_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123230","article-title":"Novel liposomal formulations for protection and delivery of levodopa: structure-properties correlation","volume":"643","author":"Allegritti","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb0655","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00210-021-02096-0","article-title":"Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease","volume":"394","author":"Rompicherla","year":"2021","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.addr.2026.115938_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2025.137695","article-title":"Nose-to-brain delivery of donepezil and \u03b1-tocopherol using cationic deformable liposomes modified with isothiuronium surfactants","volume":"725","author":"Gaynanova","year":"2025","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.addr.2026.115938_bb0665","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/pharmaceutics15020533","article-title":"Investigating the targeting power to brain tissues of intranasal Rasagiline Mesylate-loaded Transferosomal in situ gel for efficient treatment of Parkinson's disease","volume":"15","author":"ElShagea","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb0670","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3390\/pharmaceutics12090855","article-title":"Transfersomes: a promising Nanoencapsulation technique for transdermal drug delivery","volume":"12","author":"Opatha","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb0675","first-page":"259","article-title":"Solid lipid nanoparticles (SLN) as a novel drug delivery system: a theoretical review","volume":"11","author":"Alsaad","year":"2020","journal-title":"Systematic Reviews in Pharmacy"},{"key":"10.1016\/j.addr.2026.115938_bb0680","first-page":"1593","article-title":"Solid Lipid Nanoparticles vs","volume":"15","author":"Viegas","year":"2023","journal-title":"Nanostructured Lipid Carriers: A Comparative Review, Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb0685","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/pharmaceutics13081183","article-title":"Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB","volume":"13","author":"Satapathy","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb0690","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejpb.2021.07.015","article-title":"Dopamine-loaded lipid based nanocarriers for intranasal administration of the neurotransmitter: a comparative study","volume":"167","author":"Trapani","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2026.115938_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120881","article-title":"Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson's disease","volume":"606","author":"Uppuluri","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb0700","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3390\/molecules27010289","article-title":"Nanostructured lipid carriers-hydrogels system for drug delivery: Nanohybrid technology perspective","volume":"27","author":"Syed Azhar","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115938_bb0705","first-page":"122","article-title":"A review of the structure","volume":"7","author":"Li","year":"2017","journal-title":"Preparation Application of NLCs, PNPs, and PLNs, Nanomaterials"},{"key":"10.1016\/j.addr.2026.115938_bb0710","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1039\/D4PM00174E","article-title":"Nose to brain targeting of the donepezil nanostructured lipid carrier in situ gel: formulation, in vitro, ex vivo, in vivo pharmacokinetic and pharmacodynamic characterization","volume":"1","author":"Sonawane","year":"2024","journal-title":"RSC Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb0715","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s11671-025-04276-w","article-title":"Nose to brain delivery of nanostructured lipid carriers loaded with rivastigmine and nilotinib for treating Alzheimer's disease: preparation, cell line study, and in vivo evaluation","volume":"20","author":"Khan","year":"2025","journal-title":"Discover Nano"},{"key":"10.1016\/j.addr.2026.115938_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.143236","article-title":"Hyaluronate-incorporated edaravone nanostructured lipid carriers for nose-to-brain targeting- biphasic DoE optimization, pharmacokinetic, and brain distribution studies","volume":"310","author":"Patel","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2026.115938_bb0725","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/pharmaceutics16010058","article-title":"Intranasal drug delivery by nanotechnology: advances in and challenges for Alzheimer's disease management","volume":"16","author":"Dighe","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb0730","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/jnt5040012","article-title":"Characteristics and preparation of solid lipid nanoparticles and nanostructured lipid carriers","volume":"5","author":"Queiroz","year":"2024","journal-title":"J. Nanotheranostics"},{"key":"10.1016\/j.addr.2026.115938_bb0735","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/colloids7010023","article-title":"Nose-to-brain targeting via Nanoemulsion: significance and evidence","volume":"7","author":"Misra","year":"2023","journal-title":"Colloids Interfaces"},{"key":"10.1016\/j.addr.2026.115938_bb0740","first-page":"1","article-title":"Efficient nose-to-brain delivery of chitosan-coated resveratrol nanoemulsion in rats: formulation optimized using D-optimal mixture design","author":"Yadav","year":"2026","journal-title":"J. Dispers. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115938_bb0745","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.2147\/IJN.S369978","article-title":"Investigation of the \u201cnose-to-brain\u201d pathways in intranasal HupA Nanoemulsions and evaluation of their in vivo pharmacokinetics and brain-targeting ability","volume":"17","author":"Jiang","year":"2022","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2026.115938_bb0750","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.partic.2021.05.009","article-title":"Nanoemulsions for drug delivery","volume":"64","author":"Wilson","year":"2022","journal-title":"Particuology"},{"key":"10.1016\/j.addr.2026.115938_bb0755","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115938_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126011","article-title":"Intranasal delivery of rapamycin via brain-targeting polymeric micelles for Alzheimer's disease treatment","volume":"683","author":"Sugandhi","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105960","article-title":"Development of dexamethasone-loaded mixed polymeric micelles for nasal delivery","volume":"166","author":"Sipos","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112905","article-title":"Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: an opportunity to develop new CNS drugs","volume":"209","author":"Mignani","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115938_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.105336","article-title":"Novel ligand conjugated poly(propylene imine) dendrimers for brain targeted delivery of tacrine hydrochloride","volume":"92","author":"Sahu","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.addr.2026.115938_bb0780","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3390\/polym16142022","article-title":"Polyamidoamine dendrimers: brain-targeted drug delivery systems in glioma therapy","volume":"16","author":"Yan","year":"2024","journal-title":"Polymers"},{"key":"10.1016\/j.addr.2026.115938_bb0785","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jcis.2018.11.029","article-title":"Drug loading augmentation in polymeric nanoparticles using a coaxial turbulent jet mixer: Yong investigator perspective","volume":"538","author":"Lim","year":"2019","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.addr.2026.115938_bb0790","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/17425247.2024.2375400","article-title":"Understanding nanoparticle-liver interactions in nanomedicine","volume":"21","author":"He","year":"2024","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115938_bb0795","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13036-022-00298-5","article-title":"Dendrimer-based drug delivery systems: history, challenges, and latest developments","volume":"16","author":"Wang","year":"2022","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.addr.2026.115938_bb0800","doi-asserted-by":"crossref","first-page":"14041","DOI":"10.3390\/ijms241814041","article-title":"Lyophilization of nanoparticles, does it really work? Overview of the current status and challenges","volume":"24","author":"Gatto","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb0805","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.3390\/molecules30132878","article-title":"Cyclodextrin-based quercetin powders for potential nose-to-brain transport: formulation and in vitro assessment","volume":"30","author":"Saitani","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115938_bb0810","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s13346-023-01477-7","article-title":"Freeze-drying revolution: unleashing the potential of lyophilization in advancing drug delivery systems","volume":"14","author":"Arora","year":"2024","journal-title":"Drug Deliv. and Transl. Res."},{"key":"10.1016\/j.addr.2026.115938_bb0815","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3390\/pharmaceutics14081742","article-title":"Development and in vitro-ex vivo evaluation of novel polymeric nasal donepezil films for potential use in Alzheimer's disease using experimental design","volume":"14","author":"Papakyriakopoulou","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb0820","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1208\/s12249-022-02351-4","article-title":"Design of a Personalized Nasal Device (matrix-piston nasal device, MPD) for drug delivery: a 3D-printing application","volume":"23","author":"Menegatou","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2026.115938_bb0825","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/pharmaceutics15051409","article-title":"Donepezil brain and blood pharmacokinetic modeling after nasal film and Oral solution Administration in Mice","volume":"15","author":"Kaikousidis","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb0830","series-title":"FDA no longer needs to require animal tests before human drug trials","year":"2026"},{"key":"10.1016\/j.addr.2026.115938_bb0835","series-title":"E.L. Buddy [R-G.-1 rep. Carter, text - H.R.7248 - 118th congress (2023-2024): FDA Modernization Act 3.0]","year":"2024"},{"key":"10.1016\/j.addr.2026.115938_bb0840","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s42826-022-00128-1","article-title":"Role of animal models in biomedical research: a review","volume":"38","author":"Mukherjee","year":"2022","journal-title":"Lab Anim Res"},{"key":"10.1016\/j.addr.2026.115938_bb0845","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/pharmaceutics14030629","article-title":"Evaluation of recent intranasal drug delivery systems to the central nervous system","volume":"14","author":"Crowe","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb0850","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2026.115938_bb0855","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1211\/0022357022539","article-title":"Is nose-to-brain transport of drugs in man a reality?","volume":"56","author":"Illum","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2026.115938_bb0860","first-page":"105","article-title":"Estimation of nasal cavity and conchae volumes by stereological method","volume":"71","author":"Emirzeoglu","year":"2012","journal-title":"Folia Morphol. (Warsz)"},{"key":"10.1016\/j.addr.2026.115938_bb0865","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1517\/17425247.5.10.1159","article-title":"From nose to brain: understanding transport capacity and transport rate of drugs","volume":"5","author":"Wu","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115938_bb0870","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1601-183X.2003.00053.x","article-title":"Linking genes to brain, behavior and neurological diseases: what can we learn from zebrafish?","volume":"3","author":"Guo","year":"2004","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.addr.2026.115938_bb0875","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1517\/17460440902988464","article-title":"Using zebrafish to assess the impact of drugs on neural development and function","volume":"4","author":"Guo","year":"2009","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.addr.2026.115938_bb0880","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/01677063.2017.1359589","article-title":"Zebrafish: from genes and neurons to circuits, behavior and disease","volume":"31","author":"Chandrasekhar","year":"2017","journal-title":"J. Neurogenet."},{"key":"10.1016\/j.addr.2026.115938_bb0885","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.ntt.2004.06.014","article-title":"Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease","volume":"26","author":"Bretaud","year":"2004","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.addr.2026.115938_bb0890","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/toxics4030019","article-title":"Zebrafish get connected: investigating neurotransmission targets and alterations in chemical toxicity","volume":"4","author":"Horzmann","year":"2016","journal-title":"Toxics"},{"key":"10.1016\/j.addr.2026.115938_bb0895","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tips.2013.12.002","article-title":"Zebrafish as an emerging model for studying complex brain disorders","volume":"35","author":"Kalueff","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb0900","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s004290050232","article-title":"Postembryonic neural proliferation in the zebrafish forebrain and its relationship to prosomeric domains","volume":"199","author":"Wullimann","year":"1999","journal-title":"Anat. Embryol. (Berl)"},{"key":"10.1016\/j.addr.2026.115938_bb0905","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/(SICI)1097-4695(199604)29:4<445::AID-NEU3>3.0.CO;2-8","article-title":"Ontogeny of odorant receptor gene expression in zebrafish, Danio rerio","volume":"29","author":"Byrd","year":"1996","journal-title":"J. Neurobiol."},{"key":"10.1016\/j.addr.2026.115938_bb0910","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077548","article-title":"Functional characterisation of the maturation of the blood-brain barrier in larval zebrafish","volume":"8","author":"Fleming","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2026.115938_bb0915","series-title":"Zebrafish as a Translational Model: An Experimental Alternative to Study the Mechanisms Involved in Anosmia and Possible Neurodegenerative Aspects of COVID-19?, eNeuro 8","author":"Costa","year":"2021"},{"key":"10.1016\/j.addr.2026.115938_bb0920","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.celrep.2018.01.019","article-title":"Terminal nerve GnRH3 neurons mediate slow avoidance of carbon dioxide in larval zebrafish","volume":"22","author":"Koide","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2026.115938_bb0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e33865","article-title":"Zebrafish as a model organism for virus disease research: current status and future directions","volume":"10","author":"Sofyantoro","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.addr.2026.115938_bb0930","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41684-025-01545-0","article-title":"Intranasal delivery of drugs to the central nervous system of adult zebrafish","volume":"54","author":"Galstyan","year":"2025","journal-title":"Lab. Anim."},{"key":"10.1016\/j.addr.2026.115938_bb0935","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12987-018-0108-3","article-title":"A perfused human blood-brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport","volume":"15","author":"Wevers","year":"2018","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.addr.2026.115938_bb0940","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1021\/acsabm.9b00305","article-title":"In vitro blood-brain barrier models for nanomedicine: particle-specific effects and methodological drawbacks","volume":"2","author":"Sitia","year":"2019","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.addr.2026.115938_bb0945","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ajhg.2018.10.009","article-title":"Human models are needed for studying human neurodevelopmental disorders","volume":"103","author":"Zhao","year":"2018","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.addr.2026.115938_bb0950","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1038\/s41467-021-26066-5","article-title":"Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption","volume":"12","author":"Pediaditakis","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115938_bb0955","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.76707","article-title":"Generation of vascularized brain organoids to study neurovascular interactions","volume":"11","author":"Sun","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.addr.2026.115938_bb0960","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1177\/1535370217694100","article-title":"Blood-brain barrier-on-a-chip: microphysiological systems that capture the complexity of the blood-central nervous system interface","volume":"242","author":"Phan","year":"2017","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.addr.2026.115938_bb0965","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41467-019-13896-7","article-title":"Microengineered human blood-brain barrier platform for understanding nanoparticle transport mechanisms","volume":"11","author":"Ahn","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115938_bb0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104813","article-title":"A microengineered Brain-Chip to model neuroinflammation in humans","volume":"25","author":"Pediaditakis","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.addr.2026.115938_bb0975","article-title":"Blood-brain barrier dysfunction in a 3D in vitro model of Alzheimer's disease","volume":"6","author":"Shin","year":"2019","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.addr.2026.115938_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2025.101323","article-title":"Brain organoids-on-chip for neural diseases modeling: history, challenges and trends","author":"Zhang","year":"2025","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.addr.2026.115938_bb0985","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11082198","article-title":"Computational, In Vitro, and In Vivo Models for Nose-to-Brain Drug Delivery Studies","volume":"11","author":"Boyuklieva","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2026.115938_bb0990","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/bdd.2348","article-title":"In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose-to-brain drug delivery","volume":"44","author":"Haasbroek-Pheiffer","year":"2023","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.addr.2026.115938_bb0995","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.addr.2020.09.002","article-title":"In vitro - in vivo correlation of intranasal drug deposition","volume":"170","author":"Le Guellec","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115938_bb1000","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/17425247.2024.2336494","article-title":"Characterizing regional drug delivery within the nasal airways","volume":"21","author":"Chen","year":"2024","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115938_bb1005","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1089\/jamp.2011.0924","article-title":"Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump","volume":"25","author":"Djupesland","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115938_bb1010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijpharm.2019.02.026","article-title":"How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods","volume":"561","author":"Salade","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb1015","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3390\/pharmaceutics13071079","article-title":"In vitro evaluation of nasal aerosol depositions: an insight for direct nose to brain drug delivery","volume":"13","author":"Maaz","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb1020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/jamp.2012.1011","article-title":"Design of experiments to optimize an in vitro cast to predict human nasal drug deposition","volume":"27","author":"Shah","year":"2014","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115938_bb1025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1089\/jam.2007.0638","article-title":"The influence of spray properties on intranasal deposition","volume":"20","author":"Foo","year":"2007","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.addr.2026.115938_bb1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121858","article-title":"Anatomically realistic nasal replicas capturing the range of nasal spray drug delivery in adults","volume":"622","author":"Alfaifi","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaerosci.2024.106387","article-title":"In vitro evaluation of intersubject variability in pediatric intranasal drug delivery using nasal spray suspension products","volume":"179","author":"Esmaeili","year":"2024","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/jamp.2008.0713","article-title":"Interindividual variability in nasal filtration as a function of nasal cavity geometry","volume":"22","author":"Garcia","year":"2009","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115938_bb1045","first-page":"1063","article-title":"Particle deposition in human nasal airway replicas manufactured by different methods","volume":"38","author":"Kelly","year":"2004","journal-title":"Part I: Inertial Regime Particles, Aerosol Sci. Technol."},{"key":"10.1016\/j.addr.2026.115938_bb1050","first-page":"1072","article-title":"Particle deposition in human nasal airway replicas manufactured by different methods","volume":"38","author":"Kelly","year":"2004","journal-title":"Part II: Ultrafine Particles, Aerosol Science and Technology"},{"key":"10.1016\/j.addr.2026.115938_bb1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120103","article-title":"In vitro evaluation of regional nasal drug delivery using multiple anatomical nasal replicas of adult human subjects and two nasal sprays","volume":"593","author":"Manniello","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb1060","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/jamp.2013.1084","article-title":"Experimental measurements and computational predictions of regional particle deposition in a sectional nasal model","volume":"28","author":"Schroeter","year":"2015","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115938_bb1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124743","article-title":"Anatomically-detailed segmented representative adult and pediatric nasal models for assessing regional drug delivery and bioequivalence with suspension nasal sprays","volume":"666","author":"Khadka","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb1070","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s11095-016-1896-2","article-title":"Visualization and quantification of nasal and olfactory deposition in a sectional adult nasal airway cast","volume":"33","author":"Xi","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115938_bb1075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaerosci.2022.106101","article-title":"Effects of nasal anatomical characteristics and administration parameters on delivery of locally-acting drugs with suspension nasal sprays in adults","volume":"167","author":"Hosseini","year":"2023","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1089\/jamp.2013.1075","article-title":"Pediatric in vitro and in silico models of deposition via oral and nasal inhalation","volume":"27","author":"Carrigy","year":"2014","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115938_bb1085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbiomech.2019.109434","article-title":"In silico approaches to respiratory nasal flows: a review","volume":"97","author":"Inthavong","year":"2019","journal-title":"J. Biomech."},{"key":"10.1016\/j.addr.2026.115938_bb1090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/jam.2006.0531","article-title":"Characterization of deposition from nasal spray devices using a computational fluid dynamics model of the human nasal passages","volume":"20","author":"Kimbell","year":"2007","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.addr.2026.115938_bb1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaerosci.2023.106246","article-title":"Nasal steroid spray simulations using measured spray characteristics in healthy and rhinitic nasal passages","volume":"174","author":"Kimbell","year":"2023","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122118","article-title":"Validation and sensitivity analysis for a nasal spray deposition computational model","volume":"626","author":"Calmet","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb1105","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.compbiomed.2008.03.008","article-title":"Optimising nasal spray parameters for efficient drug delivery using computational fluid dynamics","volume":"38","author":"Inthavong","year":"2008","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.addr.2026.115938_bb1110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaerosci.2010.11.008","article-title":"Simulation of sprayed particle deposition in a human nasal cavity including a nasal spray device","volume":"42","author":"Inthavong","year":"2011","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122718","article-title":"Establishing quantitative relationships between changes in nasal spray in vitro metrics and drug delivery to the posterior nasal region","volume":"635","author":"Kolanjiyil","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb1120","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/02786826.2021.2011830","article-title":"Validating CFD predictions of nasal spray deposition: inclusion of cloud motion effects for two spray pump designs","volume":"56","author":"Kolanjiyil","year":"2022","journal-title":"Aerosol Sci. Technol."},{"key":"10.1016\/j.addr.2026.115938_bb1125","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/pharmaceutics14050956","article-title":"Importance of Spray-Wall interaction and post-deposition liquid motion in the transport and delivery of pharmaceutical nasal sprays","volume":"14","author":"Kolanjiyil","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb1130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaerosci.2021.105770","article-title":"Importance of cloud motion and two-way momentum coupling in the transport of pharmaceutical nasal sprays","volume":"156","author":"Kolanjiyil","year":"2021","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1135","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/jamp.2009.0776","article-title":"A computational fluid dynamics model for drug delivery in a nasal cavity with inferior turbinate hypertrophy","volume":"23","author":"Chen","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115938_bb1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123098","article-title":"Machine learning and sensitivity analysis for predicting nasal drug delivery for targeted deposition","volume":"642","author":"Calmet","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb1145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/jam.2006.19.301","article-title":"Analysis of particle deposition in the turbinate and olfactory regions using a human nasal computational fluid dynamics model","volume":"19","author":"Schroeter","year":"2006","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.addr.2026.115938_bb1150","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2025.127276","article-title":"Comparative analysis of drug deposition patterns among three commercial nasal spray brands: a computational and experimental study","volume":"425","author":"Liu","year":"2025","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.addr.2026.115938_bb1155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3390\/ph16010081","article-title":"Numerical and machine learning analysis of the parameters affecting the regionally delivered nasal dose of Nano- and Micro-sized aerosolized drugs","volume":"16","author":"Farnoud","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.addr.2026.115938_bb1160","doi-asserted-by":"crossref","first-page":"10568","DOI":"10.1038\/s41598-020-66716-0","article-title":"Numerical evaluation of spray position for improved nasal drug delivery","volume":"10","author":"Basu","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2026.115938_bb1165","doi-asserted-by":"crossref","DOI":"10.1016\/j.powtec.2023.118534","article-title":"Numerical simulation investigation of drug deposition process during nasal administration with auxiliary airflow","volume":"426","author":"Ren","year":"2023","journal-title":"Powder Technol."},{"key":"10.1016\/j.addr.2026.115938_bb1170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.resp.2012.12.005","article-title":"Modeling of release position and ventilation effects on olfactory aerosol drug delivery","volume":"186","author":"Si","year":"2013","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.addr.2026.115938_bb1175","first-page":"53902","article-title":"Modeling and simulations of olfactory drug delivery with passive and active controls of nasally inhaled pharmaceutical aerosols","author":"Si","year":"2016","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.addr.2026.115938_bb1180","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1089\/jamp.2016.1295","article-title":"Nasal and olfactory deposition with Normal and bidirectional intranasal delivery techniques: In Vitro Tests and Numerical Simulations","volume":"30","author":"Xi","year":"2017","journal-title":"J. Aerosol. Med. Pulm. Drug. Deliv."},{"key":"10.1016\/j.addr.2026.115938_bb1185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125086","article-title":"Computational study of the impact of nasal vestibule anatomy on nasal drug administration with nasal spray","volume":"669","author":"Shen","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb1190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaerosci.2021.105757","article-title":"Computational analysis of a 3D mucociliary clearance model predicting nasal drug uptake","volume":"155","author":"Chari","year":"2021","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaerosci.2022.106021","article-title":"Effects of subject-variability on nasally inhaled drug deposition, uptake, and clearance","volume":"165","author":"Chari","year":"2022","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1200","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jbiomech.2019.01.015","article-title":"Development of a computational fluid dynamics model for mucociliary clearance in the nasal cavity","volume":"85","author":"Shang","year":"2019","journal-title":"J. Biomech."},{"key":"10.1016\/j.addr.2026.115938_bb1205","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00397-021-01274-4","article-title":"A nonlinear viscoelastic model of mucociliary clearance","volume":"60","author":"Sedaghat","year":"2021","journal-title":"Rheol. Acta"},{"key":"10.1016\/j.addr.2026.115938_bb1210","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1248\/bpb.b14-00398","article-title":"The effect of cilia and the mucociliary clearance on successful drug delivery","volume":"38","author":"Gizurarson","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2026.115938_bb1215","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/10917691.1994.12288923","article-title":"Comparison of four biologically based dosimetry models for the deposition of rapidly metabolized vapors in the rodent nasal cavity","volume":"6","author":"Frederick","year":"1994","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.addr.2026.115938_bb1220","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/10917691.1994.12290220","article-title":"Physiologically based pharmacokinetic model for nasal uptake and metabolism of nonreactive vapors","volume":"6","author":"Morris","year":"1994","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.addr.2026.115938_bb1225","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.tox.2013.04.009","article-title":"Nasal dosimetry of inspired naphthalene vapor in the male and female B6C3F1 mouse","volume":"309","author":"Morris","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.addr.2026.115938_bb1230","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/taap.1998.8407","article-title":"A CFD-PBPK hybrid model for simulating gas and vapor uptake in the rat nose","volume":"150","author":"Bush","year":"1998","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.addr.2026.115938_bb1235","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/08958370802598005","article-title":"Magnetic resonance imaging and computational fluid dynamics (CFD) simulations of rabbit nasal airflows for the development of hybrid CFD\/PBPK models","volume":"21","author":"Corley","year":"2009","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.addr.2026.115938_bb1240","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/toxsci\/57.2.312","article-title":"Application of a hybrid CFD-PBPK nasal dosimetry model in an inhalation risk assessment: an example with acrylic acid","volume":"57","author":"Andersen","year":"2000","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1245","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1006\/rtph.2002.1576","article-title":"Physiologically based pharmacokinetic (PBPK) models for nasal tissue dosimetry of organic esters: assessing the state-of-knowledge and risk assessment applications with methyl methacrylate and vinyl acetate","volume":"36","author":"Andersen","year":"2002","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.addr.2026.115938_bb1250","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/08958378.2014.896059","article-title":"A hybrid CFD-PBPK model for naphthalene in rat and human with IVIVE for nasal tissue metabolism and cross-species dosimetry","volume":"26","author":"Campbell","year":"2014","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.addr.2026.115938_bb1255","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/toxsci\/kfs168","article-title":"Comparative computational modeling of airflows and vapor dosimetry in the respiratory tracts of rat, monkey, and human","volume":"128","author":"Corley","year":"2012","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1260","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/taap.1998.8492","article-title":"Application of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry extrapolation of acidic vapors in the upper airways","volume":"152","author":"Frederick","year":"1998","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.addr.2026.115938_bb1265","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/08958370151126248","article-title":"A hybrid computational fluid dynamics and physiologically based pharmacokinetic model for comparison of predicted tissue concentrations of acrylic acid and other vapors in the rat and human nasal cavities following inhalation exposure","volume":"13","author":"Frederick","year":"2001","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.addr.2026.115938_bb1270","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1006\/taap.2002.9451","article-title":"Use of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry comparisons of ester vapors","volume":"183","author":"Frederick","year":"2002","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.addr.2026.115938_bb1275","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/toxsci\/kfh116","article-title":"Ethyl acrylate risk assessment with a hybrid computational fluid dynamics and physiologically based nasal dosimetry model","volume":"79","author":"Sweeney","year":"2004","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1280","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/08958370151126284","article-title":"Physiologically based clearance\/extraction models for compounds metabolized in the nose: an example with methyl methacrylate","volume":"13","author":"Andersen","year":"2001","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.addr.2026.115938_bb1285","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0378-4274(02)00370-3","article-title":"Physiologically-based kinetic modeling of vapours toxic to the respiratory tract","volume":"138","author":"Bogdanffy","year":"2003","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.addr.2026.115938_bb1290","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/08958370490464562","article-title":"Interspecies dose extrapolation for inhaled dimethyl sulfate: a PBPK model-based analysis using nasal cavity N7-methylguanine adducts","volume":"16","author":"Sarangapani","year":"2004","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.addr.2026.115938_bb1295","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/08958370801903750","article-title":"A PBPK model for evaluating the impact of aldehyde dehydrogenase polymorphisms on comparative rat and human nasal tissue acetaldehyde dosimetry","volume":"20","author":"Teeguarden","year":"2008","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.addr.2026.115938_bb1300","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/toxsci\/kfi091","article-title":"Validation of human physiologically based pharmacokinetic model for vinyl acetate against human nasal dosimetry data","volume":"85","author":"Hinderliter","year":"2005","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1305","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/1420326X17694475","article-title":"Numerical prediction of tissue dosimetry in respiratory tract using computer simulated person integrated with physiologically based pharmacokinetic\u2013computational fluid dynamics hybrid analysis","volume":"27","author":"Yoo","year":"2018","journal-title":"Indoor Built Environ."},{"key":"10.1016\/j.addr.2026.115938_bb1310","first-page":"1480","article-title":"A physiologically based pharmacokinetic model for predicting diazepam pharmacokinetics after intravenous","volume":"13","author":"Khalid","year":"2021","journal-title":"Oral, Intranasal, and Rectal Applications, Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb1315","article-title":"Semi-PBPK modeling and simulation to evaluate the local and systemic pharmacokinetics of OC-01(Varenicline) nasal spray","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2026.115938_bb1320","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40262-022-01123-4","article-title":"Prediction of drug-drug interactions after Esketamine intranasal administration using a physiologically based pharmacokinetic model","volume":"61","author":"Willemin","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2026.115938_bb1325","author":"Hossain"},{"key":"10.1016\/j.addr.2026.115938_bb1330","first-page":"257","article-title":"A physiologically-based pharmacokinetic model framework to estimate systemic bioavailability of fluticasone propionate nasal spray, respiratory","volume":"2","author":"Schroeter","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2026.115938_bb1335","first-page":"197","article-title":"A physiologically-based pharmacokinetic model to estimate absorption and bioavailability of corticosteriod nasal sprays","author":"Schroeter","year":"2022","journal-title":"Respiratory Drug Delivery"},{"key":"10.1016\/j.addr.2026.115938_bb1340","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1089\/jamp.2015.1252","article-title":"Absorption and clearance of pharmaceutical aerosols in the human nose: development of a CFD model","volume":"29","author":"Rygg","year":"2016","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115938_bb1345","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s11095-015-1837-5","article-title":"Absorption and clearance of pharmaceutical aerosols in the human nose: effects of nasal spray suspension particle size and properties","volume":"33","author":"Rygg","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115938_bb1350","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.xphs.2016.03.033","article-title":"Linking suspension nasal spray drug deposition patterns to pharmacokinetic profiles: a proof-of-concept study using computational fluid dynamics","volume":"105","author":"Rygg","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124660","article-title":"CFD-PK model for nasal suspension sprays: validation with human adult in vivo data for triamcinolone acetonide","volume":"665","author":"Dutta","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb1360","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jconrel.2024.12.049","article-title":"Nasal absorption of oxycodone predicted using a novel computational fluid dynamics-physiologically based pharmacokinetic model","volume":"378","author":"Walenga","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115938_bb1365","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaerosci.2021.105898","article-title":"An effective PBPK model predicting dissolved drug transfer from a representative nasal cavity to the blood stream","volume":"160","author":"Dave","year":"2022","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1370","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1378\/chest.12-1183","article-title":"Aging, diabetes, and hypertension are associated with decreased nasal Mucociliary clearance","volume":"143","author":"Proen\u00e7a de Oliveira-Maul","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.addr.2026.115938_bb1375","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00228-004-0763-y","article-title":"Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays","volume":"60","author":"Daley-Yates","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2026.115938_bb1380","first-page":"H299","article-title":"Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat","volume":"235","author":"Ohno","year":"1978","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.addr.2026.115938_bb1385","first-page":"R303","article-title":"Distributed model for drug delivery to CSF and brain tissue","volume":"245","author":"Collins","year":"1983","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.addr.2026.115938_bb1390","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/dmd.108.023119","article-title":"Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats","volume":"37","author":"Kielbasa","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.addr.2026.115938_bb1395","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1124\/dmd.111.043554","article-title":"Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses","volume":"40","author":"Kielbasa","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.addr.2026.115938_bb1400","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1002\/jps.23266","article-title":"Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone","volume":"101","author":"Ball","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1405","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1021\/mp400533q","article-title":"A physiologically based modeling strategy during preclinical CNS drug development","volume":"11","author":"Ball","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb1410","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/pharmaceutics6010097","article-title":"Development of a physiologically-based pharmacokinetic model of the rat central nervous system","volume":"6","author":"Badhan","year":"2014","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb1415","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/pharmaceutics10010014","article-title":"Development of a region-specific physiologically based pharmacokinetic brain model to assess Hippocampus and frontal cortex pharmacokinetics","volume":"10","author":"Zakaria","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb1420","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10928-019-09641-8","article-title":"A translational platform PBPK model for antibody disposition in the brain","volume":"46","author":"Chang","year":"2019","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.addr.2026.115938_bb1425","doi-asserted-by":"crossref","first-page":"14342","DOI":"10.1038\/s41598-023-41382-0","article-title":"Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model","volume":"13","author":"Geerts","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2026.115938_bb1430","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/psp4.12912","article-title":"A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease","volume":"12","author":"Geerts","year":"2023","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.addr.2026.115938_bb1435","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10928-021-09800-w","article-title":"Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system","volume":"49","author":"Chang","year":"2022","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.addr.2026.115938_bb1440","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10928-021-09776-7","article-title":"Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases","volume":"48","author":"Bloomingdale","year":"2021","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.addr.2026.115938_bb1445","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4161\/mabs.23684","article-title":"Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human","volume":"5","author":"Shah","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115938_bb1450","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1208\/s12248-024-00898-7","article-title":"Investigation of antibody pharmacokinetics in the brain following intra-CNS Administration and development of PBPK model to characterize the data","volume":"26","author":"Wu","year":"2024","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115938_bb1455","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1208\/s12248-012-9366-1","article-title":"Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats","volume":"14","author":"Westerhout","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115938_bb1460","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10928-013-9314-4","article-title":"The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid","volume":"40","author":"Westerhout","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.addr.2026.115938_bb1465","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejps.2013.12.020","article-title":"Prediction of methotrexate CNS distribution in different species - influence of disease conditions","volume":"57","author":"Westerhout","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1470","series-title":"Blood-Brain Barrier in Drug Discovery","first-page":"296","article-title":"PBPK modeling approach for predictions of human CNS drug brain distribution","author":"de Lange","year":"2015"},{"key":"10.1016\/j.addr.2026.115938_bb1475","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11095-016-2065-3","article-title":"A generic multi-compartmental CNS distribution model structure for 9 drugs allows prediction of human brain target site concentrations","volume":"34","author":"Yamamoto","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115938_bb1480","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/psp4.12250","article-title":"Predicting drug concentration-time profiles in multiple CNS compartments using a comprehensive physiologically-based pharmacokinetic model","volume":"6","author":"Yamamoto","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.addr.2026.115938_bb1485","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejps.2017.11.011","article-title":"Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach","volume":"112","author":"Yamamoto","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1490","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10928-021-09768-7","article-title":"Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations","volume":"48","author":"Saleh","year":"2021","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.addr.2026.115938_bb1495","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/pharmaceutics13010095","article-title":"Impact of CNS diseases on drug delivery to brain extracellular and intracellular target sites in human: a \u201cWHAT-IF\u201d simulation study","volume":"13","author":"Saleh","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb1500","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s11095-023-03554-5","article-title":"Using the LeiCNS-PK3.0 physiologically-based pharmacokinetic model to predict brain extracellular fluid pharmacokinetics in mice","volume":"40","author":"Saleh","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115938_bb1505","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3390\/pharmaceutics14091764","article-title":"Revisiting cerebrospinal fluid flow direction and rate in physiologically based pharmacokinetic model","volume":"14","author":"Hirasawa","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb1510","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.dmpk.2016.03.005","article-title":"Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: estimating time varying CSF drug concentrations and their variability using in vitro data","volume":"31","author":"Gaohua","year":"2016","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.addr.2026.115938_bb1515","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-22-0405","article-title":"Mechanistic modeling of central nervous system pharmacokinetics and target engagement of HER2 tyrosine kinase inhibitors to inform treatment of breast Cancer brain metastases","volume":"28","author":"Li","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2026.115938_bb1520","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1158\/1078-0432.CCR-17-0983","article-title":"Quantitative and mechanistic understanding of AZD1775 penetration across human blood-brain barrier in glioblastoma patients using an IVIVE-PBPK modeling approach","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2026.115938_bb1525","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/00498254.2024.2349046","article-title":"Pharmacokinetics of intranasal drugs, still a missed opportunity?","volume":"54","author":"Sardu","year":"2024","journal-title":"Xenobiotica"},{"key":"10.1016\/j.addr.2026.115938_bb1530","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10928-019-09648-1","article-title":"Computational framework for predictive PBPK-PD-Tox simulations of opioids and antidotes","volume":"46","author":"German","year":"2019","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.addr.2026.115938_bb1535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007117","article-title":"Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis","volume":"15","author":"Verscheijden","year":"2019","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.addr.2026.115938_bb1540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1008786","article-title":"Physiologically based pharmacokinetic\/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children","volume":"17","author":"Verscheijden","year":"2021","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.addr.2026.115938_bb1545","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2021.105223","article-title":"Application of in vitro data in physiologically-based kinetic models for quantitative in vitro-in vivo extrapolation: a case-study for baclofen","volume":"76","author":"Kasteel","year":"2021","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.addr.2026.115938_bb1550","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/pharmaceutics16020226","article-title":"Interspecies brain PBPK modeling platform to predict passive transport through the blood-brain barrier and assess target site disposition","volume":"16","author":"Mehta","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115938_bb1555","series-title":"GastroPlus\u00ae PBBM \/ PBPK","year":"2025"},{"key":"10.1016\/j.addr.2026.115938_bb1560","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0928-0987(02)00132-X","article-title":"Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA","volume":"17","author":"Parrott","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115938_bb1565","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fphys.2011.00004","article-title":"A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks","volume":"2","author":"Eissing","year":"2011","journal-title":"Front. Physiol."},{"key":"10.1016\/j.addr.2026.115938_bb1570","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1478-5382(03)02342-4","article-title":"PK-Sim\u00ae: a physiologically based pharmacokinetic \u2018whole-body\u2019 model","volume":"1","author":"Willmann","year":"2003","journal-title":"BIOSILICO"},{"key":"10.1016\/j.addr.2026.115938_bb1575","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/17425255.1.1.159","article-title":"From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools","volume":"1","author":"Willmann","year":"2005","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.addr.2026.115938_bb1580","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","article-title":"Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs","volume":"34","author":"Willmann","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.addr.2026.115938_bb1585","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/jcph.1365","article-title":"Physiologically based modeling approach to predict dopamine D2 receptor occupancy of antipsychotics in brain: translation from rat to human","volume":"59","author":"Wong","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2026.115938_bb1590","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/bdd.2282","article-title":"Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment","volume":"42","author":"Alsmadi","year":"2021","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.addr.2026.115938_bb1595","doi-asserted-by":"crossref","first-page":"9245","DOI":"10.1021\/acsomega.4c09472","article-title":"Physiologically based pharmacokinetic model of plasma and intracranial pharmacokinetics and CDK4\/6 occupancy of Abemaciclib to optimizing dosing regimen for brain metastatic patients","volume":"10","author":"Zhang","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.addr.2026.115938_bb1600","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00280-019-03941-z","article-title":"Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice","volume":"84","author":"Hughes","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2026.115938_bb1605","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10928-017-9559-4","article-title":"A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim","volume":"45","author":"Niederalt","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.addr.2026.115938_bb1610","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1124\/dmd.111.040782","article-title":"Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration","volume":"39","author":"Stevens","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.addr.2026.115938_bb1615","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10928-012-9262-4","article-title":"Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans","volume":"39","author":"Stevens","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.addr.2026.115938_bb1620","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11095-019-2610-y","article-title":"Mathematical modeling and simulation to investigate the CNS transport characteristics of Nanoemulsion-based drug delivery following intranasal administration","volume":"36","author":"Kadakia","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115938_bb1625","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5414\/CP204217","article-title":"Novel intranasal treatment for anxiety disorders using amiloride, an acid-sensing ion channel antagonist: pharmacokinetic modeling and simulation","volume":"60","author":"Azzeh","year":"2022","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2026.115938_bb1630","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125392","article-title":"A comprehensive analytical model for predicting drug absorption in the olfactory region: application to nose-to-brain delivery","volume":"674","author":"Rigaut","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115938_bb1635","series-title":"FY 2022 GDUFA Science and Research Report","author":"C. for D.E. and Research","year":"2024"},{"key":"10.1016\/j.addr.2026.115938_bb1640","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000348347","volume":"35","author":"Morimoto","year":"2013","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.addr.2026.115938_bb1645","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide for progressive Supranuclear palsy: a multicenter, randomized, double-blind, placebo controlled trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.addr.2026.115938_bb1650","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/mds.26351","article-title":"Double-blind phase I\/IIa study of intranasal glutathione in Parkinson\u2019s disease","volume":"30","author":"Mischley","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.addr.2026.115938_bb1655","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3233\/JPD-161040","article-title":"Phase IIb study of intranasal glutathione in Parkinson's disease","volume":"7","author":"Mischley","year":"2026","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.addr.2026.115938_bb1660","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214364","article-title":"Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: a double-blinded placebo-controlled pilot study","volume":"14","author":"Novak","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2026.115938_bb1665","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70704","article-title":"A phase 2A\/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD","volume":"21","author":"Erichsen","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.addr.2026.115938_bb1670","article-title":"First-in-human positron emission tomography study of intranasal insulin in aging and MCI","volume":"11","author":"Sai","year":"2025","journal-title":"Alzheimers Dement (N Y)"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:19:32Z","timestamp":1789121972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26001729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":334,"alternative-id":["S0169409X26001729"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115938","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal drug delivery to the brain for neurodegenerative diseases: Current efforts and challenges in delivery platforms and modeling","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115938"}}